COVID-19: The Invisible Impact on Dermatologists and Dermatology Practices
Join your dermatology colleagues and thought leaders as we examine the hidden impact of COVID-19 on dermatologists and providers, including new and small private practices, emotional wellbeing and the evolving priorities placed on providers during the global coronavirus pandemic. Panelists will discuss their first-hand, personal experience living with COVID-19 and ways it has impacted their physical and emotional health, practice and personal life.
Discussion and guidance will be given on simple steps you can take in the wellness sphere, crisis management and return to practice concepts for both large and small dermatology practices.
Moderators
- Richard G. Fried, MD, PhD (Board Certified Dermatologist & Clinical Psychologist, Clinical Director, Yardley Dermatology Associates)
Panelists
- Evan Rieder, MD (Board Certified Dermatologist & Psychiatrist, NYU Langone Health)
- Paul Jarrod Frank, MD (Chief Medical Officer & Founder, PFRANKMD)
- Melissa Kanchanapoomi Levin, MD (Founder, Entière Dermatology)
You May Also Like
JDD in the News: Topical Nonsteroidals for Chronic Hand Eczema
JDD in the News: Topical Nonsteroidals for Chronic Hand Eczema
Physician’s Weekly interviewed dermatologist Geeta Yadav, MD, for her perspective on the March Journal of Drugs in Dermatology study, “Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.”…
Efficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study
Efficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study
Topical Metformin versus Kligman’s Formula for Melasma, a Split-Face JDD Study This is a must-read article from JDD a head-to-head split-face study asks whether topical metformin can be an effective,…
Longer Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study
Longer Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study
Extended Pembrolizumab Duration Tied to Lower Mortality in Stage III and IV Melanoma: JDD Report Could extending pembrolizumab improve survival? This JDD is a must read. A new retrospective analysis…
